66 related articles for article (PubMed ID: 12879133)
1. TDM: the key to more effective HIV treatment?
Jack D
Drug News Perspect; 2000 Dec; 13(10):622-7. PubMed ID: 12879133
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
3. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir.
Donnerer J; Haas BJ; Kessler HH
Pharmacology; 2008; 82(4):287-92. PubMed ID: 18931536
[TBL] [Abstract][Full Text] [Related]
4. AIDS in the Third World: how to stop the HIV infection?
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
6. Aiming for quality as well as quantity.
Jack DB
Drug News Perspect; 1998 Dec; 11(10):653-7. PubMed ID: 15616635
[TBL] [Abstract][Full Text] [Related]
7. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
Chrysos G; Mikros S; Kokkoris S; Pastelli A; Kontochristopoulos G
J Drugs Dermatol; 2007 Jul; 6(7):742-3. PubMed ID: 17763601
[TBL] [Abstract][Full Text] [Related]
8. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.
Notari S; Bocedi A; Ippolito G; Narciso P; Pucillo LP; Tossini G; Donnorso RP; Gasparrini F; Ascenzi P
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):258-66. PubMed ID: 16406832
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Demeter LM; Ribaudo HJ; Erice A; Eshleman SH; Hammer SM; Hellmann NS; Fischl MA;
Clin Infect Dis; 2004 Aug; 39(4):552-8. PubMed ID: 15356820
[TBL] [Abstract][Full Text] [Related]
13. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
14. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
15. Drug therapy in HIV infection--fourth international congress. 8-12 November 1998, Glasgow, Scotland.
Wainberg MA
IDrugs; 1999 Jan; 2(1):18-9. PubMed ID: 16180161
[TBL] [Abstract][Full Text] [Related]
16. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
17. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
[TBL] [Abstract][Full Text] [Related]
18. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.
Vogel M; Voigt E; Michaelis HC; Sudhop T; Wolff M; Türler A; Sauerbruch T; Rockstroh JK; Spengler U
Liver Transpl; 2004 Jul; 10(7):939-44. PubMed ID: 15237382
[TBL] [Abstract][Full Text] [Related]
19. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]